← Leaderboards
Aquilur Rahman
N&N Scientific, Inc.
$3,479,710
Attributed
$3,479,710
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2009–14$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,479,710 · 2
By mechanism
R44$2,879,710 · 1
R43$600,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsHuman Herpesvirus 2Chronic DiseaseDouble Stranded Dna VirusGenital HerpesHerpesvirus 1, HumanCellsCharacteristicsCowpox VirusDoseExhibitsFaceHerpes LabialisHerpesviridaeBioavailableAcyclovirAnimalsBiological AvailabilityAdultClinical TrialsAntiviral AgentsCytotoxicityDrug ResistanceImmunocompromised Host
Grant awards (5)
N-Methanocarbathymidine (N-MCT) for the treatment of herpes and pox virus infecti$879,710
R44 · FY2014 · AI · contact PI
N-Methanocarbathymidine (N-MCT) for the treatment of herpes and pox virus infecti$1,000,000
R44 · FY2013 · AI · contact PI
N-Methanocarbathymidine (N-MCT) for the treatment of herpes and pox virus infecti$1,000,000
R44 · FY2012 · AI · contact PI
N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti$300,000
R43 · FY2010 · AI · contact PI
N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti$300,000
R43 · FY2009 · AI · contact PI